Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.76 USD 1.47% Market Closed
Market Cap: 815.2m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Abcellera Biologics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Abcellera Biologics Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Interest Income Expense
$46.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Interest Income Expense
-CA$620.6k
CAGR 3-Years
-17%
CAGR 5-Years
-43%
CAGR 10-Years
-41%
Replicel Life Sciences Inc
XTSX:RP
Interest Income Expense
-CA$395.6k
CAGR 3-Years
-146%
CAGR 5-Years
-51%
CAGR 10-Years
-29%
Innovotech Inc
XTSX:IOT
Interest Income Expense
CA$124.2k
CAGR 3-Years
200%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abcellera Biologics Inc
Glance View

Market Cap
802.7m USD
Industry
Life Sciences Tools & Services

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.67 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Interest Income Expense?
Interest Income Expense
46.1m USD

Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Interest Income Expense amounts to 46.1m USD.

What is Abcellera Biologics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
285%

Over the last year, the Interest Income Expense growth was 285%.

Back to Top